Observational Single-center Comparative Study of the Efficacy of Buffered Acetylsalicylic Acid and Enteric-coated Acetylsalicylic Acid on Platelet Aggregation in Patients With Chronic Coronary Syndrome and Type 2 Diabetes Mellitus
Patients with diabetes mellitus are characterized by "hyperreactive" platelets and a reduced response to ASA compared to individuals without diabetes. ASA that is absorbed in the intestine is slower to enter the bloodstream and become therapeutic concentrations compared to ASA that is absorbed in the stomach. It seems rational to test the hypothesis that the use of buffered ASA may be more effective in patients with diabetes and chronic coronary syndrome (CCS).
100 项与 Nizhpharm AO 相关的临床结果
0 项与 Nizhpharm AO 相关的专利（医药）
100 项与 Nizhpharm AO 相关的药物交易
100 项与 Nizhpharm AO 相关的转化医学
